Pacer Advisors
IMNM icon

Pacer Advisors’s Immunome IMNM Stock Holding History

Pacer Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29K Buy
+1,389
New +$29.7K ﹤0.01% 2173
2024
Q3 		– Sell
-660
Closed -$7.99K – 2618
2024
Q2 		$7.99K Buy
+660
New +$10.3K ﹤0.01% 3584

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Pacer Advisors's IMNM Position: Q2 2026 in Review

Pacer Advisors opened a new position in Immunome (IMNM) in Q2 2026: 1,389 shares worth $29K. The stake represents ﹤0.01% of the portfolio and ranks #2173 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in IMNM as recently as Q2 2024.

Pacer Advisors first reported a position in IMNM in Q2 2024 and has held it in 2 quarters since. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Pacer Advisors held 1,389 shares of Immunome worth $29K as of Q2 2026.
  • Immunome was a new Pacer Advisors position in Q2 2026.
  • Immunome made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2173 holding.
  • Pacer Advisors first reported a position in Immunome in Q2 2024 and has held it in 2 quarters since.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.